Inhibikase Therapeutics Inc (IKT) USD0.001

Sell:$1.61Buy:$1.79Price increased$0.02 (1.21%)

Prices delayed by at least 15 minutes
Sell:$1.61
Buy:$1.79
Change:Price increased$0.02 (1.21%)
Deal now
Prices delayed by at least 15 minutes
Sell:$1.61
Buy:$1.79
Change:Price increased$0.02 (1.21%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Key people

Christopher H. Cabell
President, Head - Research and Development
Mark T. Iwicki
Chief Executive Officer, Director
David Mcintyre
Chief Financial Officer, Principal Accounting Officer
John Adams
Chief Scientific Officer
Timothy Pigot
Chief Commercial and Strategy Officer
Amit D. Munshi
Independent Chairman of the Board
Vincent E. Aurentz
Independent Director
Roberto Bellini
Independent Director
Dennis N. Berman
Independent Director
David Canner
Independent Director
Click to see more

Key facts

  • Shares in issue
    120.90m
  • EPIC
    IKT
  • ISIN
    US45719W2052
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $205.53m
  • Employees
    15
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.